Wednesday, June 4, 2025
VISIT ROYALMOK
Agarwood Times
  • Home
  • Agarwood
  • Health
  • Diseases
  • Diet & Fitness
  • Nutrition
  • Sleep Info
  • Meditation
  • Shop
No Result
View All Result
  • Home
  • Agarwood
  • Health
  • Diseases
  • Diet & Fitness
  • Nutrition
  • Sleep Info
  • Meditation
  • Shop
No Result
View All Result
Agarwood Times
No Result
View All Result

Study in LA highlights real-world efficacy of doxyPEP

February 18, 2025
in Diseases
Reading Time: 2 mins read
0 0
A A
0
Home Diseases
Share on FacebookShare on Twitter


A research of greater than 2,000 sufferers in Los Angeles who had been prescribed doxycycline post-exposure prophylaxis (DP) discovered it was extremely efficient in stopping sexually transmitted infections (STIs), researchers reported final week in Open Discussion board Infectious Illnesses.

For the researchcarried out on the Los Angeles LGBT Heart from April 2019 to July 2024, researchers analyzed digital well being document knowledge on 2,083 sufferers who had been prescribed DP over the research interval. The middle issued formal clinician steering on DP use in October 2022. The goal of the research was to assessment affected person demographics, STI testing historical past, use patterns, and short-term effectiveness of DP.

Almost half of the sufferers had been between 31 and 40 years of age (48.1%), over half had been white (55.9%), 85.2% had been homosexual or bisexual males, and 41.4% had a historical past of a number of STI diagnoses within the 12 months previous to DP initiation. Almost 1 / 4 (24.5%) of DP sufferers obtained a prescription from January 1 to April 15, 2024.

Actual-world efficacy matches medical trial outcomes

Amongst 1,115 sufferers with 6 months or extra of DP use, circumstances of syphilis fell by 86.4%, chlamydia circumstances declined by 89.7%, and gonorrhea circumstances decreased by 54.7%. There was comparable effectiveness for chlamydia and gonorrhea no matter anatomic website (rectal or throat swabs or urine pattern).

The research authors be aware that the discount in bacterial STIs noticed amongst DP customers is just like the outcomes of the DoxyPEP trial carried out in San Francisco and Seattle. Outcomes from that trial and one other in France resulted within the Facilities for Illness Management and Prevention recommending DP in 2024 for homosexual males and transgender ladies with a historical past of STIs.

The authors say that whereas DP has grow to be “an vital and ever extra broadly used device” for bacterial STI transmission, vital questions on attainable tradeoffs or penalties of constant use stay.

“Researchers ought to intently look at use patterns and set up high quality enchancment applications in all settings the place DP use is advisable to be able to reduce adversarial outcomes whereas making an attempt to attain inhabitants influence on the STI and HIV syndemics,” they concluded.



Source link

Tags: doxyPEPefficacyhighlightsrealworldStudy
Previous Post

Third avian flu spillover reported in Arizona dairy herd; raw pet food sickens Oregon cats

Next Post

Lecanemab and donanemab slow Alzheimer’s decline, but is the benefit worth the cost?

Related Posts

Mother’s obesity linked to child’s heightened hospital admission risk for infection
Diseases

Mother’s obesity linked to child’s heightened hospital admission risk for infection

June 4, 2025
Report highlights evidence, remaining data gaps on vaccines and antibiotic resistance
Diseases

Report highlights evidence, remaining data gaps on vaccines and antibiotic resistance

June 3, 2025
MIS-C patients catch up with controls by most measures within 2 years, data suggest
Diseases

MIS-C patients catch up with controls by most measures within 2 years, data suggest

June 4, 2025
U.S. Global Health Legislation Tracker
Diseases

U.S. Global Health Legislation Tracker

June 4, 2025
Large-scale immunity profiling grants insights into flu virus evolution
Diseases

Large-scale immunity profiling grants insights into flu virus evolution

June 3, 2025
Antibody-drug conjugate shows promising safety and response rates for patients with rare blood cancer
Diseases

Antibody-drug conjugate shows promising safety and response rates for patients with rare blood cancer

June 3, 2025
Next Post
Lecanemab and donanemab slow Alzheimer’s decline, but is the benefit worth the cost?

Lecanemab and donanemab slow Alzheimer’s decline, but is the benefit worth the cost?

A cost-effective solution for personalized support at home

A cost-effective solution for personalized support at home

Memorial Sloan Kettering Teams Up with AWS to Speed Up Drug Discovery

Memorial Sloan Kettering Teams Up with AWS to Speed Up Drug Discovery

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

RECOMMENDED

MIS-C patients catch up with controls by most measures within 2 years, data suggest
Diseases

MIS-C patients catch up with controls by most measures within 2 years, data suggest

by admin
June 4, 2025
0

Two years after hospitalization for multisystem inflammatory syndrome in kids (MIS-C), most sufferers' neurologic and psychological check scores had been...

Astellas Stays Competitive in Hot Gut Cancer Target, Paying 0M to License Evopoint Drug

Astellas Stays Competitive in Hot Gut Cancer Target, Paying $130M to License Evopoint Drug

May 31, 2025
🔥This Environment Topic is Key for UPSC Prelims 2025—Don’t Miss Out!

🔥This Environment Topic is Key for UPSC Prelims 2025—Don’t Miss Out!

May 30, 2025
BMS Buys Into BioNTech Bispecific Antibody, Putting Up .5B to Collaborate in Multiple Cancers

BMS Buys Into BioNTech Bispecific Antibody, Putting Up $1.5B to Collaborate in Multiple Cancers

June 3, 2025
Report highlights evidence, remaining data gaps on vaccines and antibiotic resistance

Report highlights evidence, remaining data gaps on vaccines and antibiotic resistance

June 3, 2025
Healthy Tuscan Farro & White Bean Veggie Burgers

Healthy Tuscan Farro & White Bean Veggie Burgers

May 31, 2025
Facebook Twitter Instagram Youtube RSS
Agarwood Times

Stay informed with the latest news, articles, and insights on agarwood cultivation, history, sustainability, and more. Explore the timeless allure of agarwood and deepen your understanding of this extraordinary natural resource.

CATEGORIES

  • Agarwood
  • Diet & Fitness
  • Diseases
  • Health
  • Meditation
  • Nutrition
  • Sleep Info
  • Uncategorized
No Result
View All Result

SITEMAP

  • About us
  • Advertise With Us
  • Disclaimer
  • Privacy Policy
  • DMCA
  • Cookie Privacy Policy
  • Terms and Conditions
  • Contact us

Copyright © 2024 Agarwood Times.
Agarwood Times is not responsible for the content of external sites.

No Result
View All Result
  • Home
  • Agarwood
  • Health
  • Diseases
  • Diet & Fitness
  • Nutrition
  • Sleep Info
  • Meditation
  • Shop
VISIT ROYALMOK

Copyright © 2024 Agarwood Times.
Agarwood Times is not responsible for the content of external sites.

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In